JOHN J ORLOFF Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN J ORLOFF.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN J ORLOFF. JOHN J ORLOFF is a EVP, Research & Development in ALEXION PHARMACEUTICALS INC ($ALXN) and a Director in NOVELION THERAPEUTICS INC. ($QLTI) and a See Remarks in NOVELION THERAPEUTICS INC. ($QLTI) and a EVP and President, R&D in Baxalta Inc ($BXLT) and a See Remarks in Baxalta Inc ($BXLT).
Address: C/O BAXALTA INCORPORATED ONE BAXTER PARKWAY DEERFIELD 60015 IL
Companies in which JOHN J ORLOFF is an Insider
ALEXION PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN J ORLOFF: EVP, Research & Development
Holdings: 88,324 shares
Current Value: $11,280,741
Latest Transaction: Mar 02 2021
$ALXN Market Capitalization: $28.30B
$ALXN Previous Close: $127.72
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Baxalta Inc
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN J ORLOFF: EVP and President, R&D, See Remarks
Holdings: 0 shares
Latest Transaction: Jun 07 2016
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
NOVELION THERAPEUTICS INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN J ORLOFF: Director, See Remarks
Holdings: 0 shares
Latest Transaction: Aug 13 2018
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of JOHN J ORLOFF
Sentiment: All, ALXN, BXLT, NVLN
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 02 2021 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 24,473 | 0 | 88,324 | 63.9 K to 88.3 K (+38.33 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 93.53 | 40 | 3,741 | 63,851 | 63.8 K to 63.9 K (+0.06 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 157.96 | 3,261 | 515,108 | 63,811 | 67.1 K to 63.8 K (-4.86 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 157.96 | 18,134 | 2,864,447 | 67,072 | 85.2 K to 67.1 K (-21.28 %) |
| Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 40,677 | 0 | 85,206 | 44.5 K to 85.2 K (+91.35 %) |
| Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 114.61 | 2,784 | 319,074 | 44,529 | 47.3 K to 44.5 K (-5.88 %) |
| Jun 11 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 118.61 | 2,786 | 330,447 | 37,791 | 40.6 K to 37.8 K (-6.87 %) |